IC
LEGN icon

Ikarian Capital’s Legend Biotech LEGN Stock Holding History

Ikarian Capital’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,500
Closed -$44K – 254
2021
Q1 		$44K Buy
+1,500
New +$40.9K ﹤0.01% 285

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FBIL
First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Ikarian Capital's LEGN Position: Q1 2026 in Review

Ikarian Capital held its Legend Biotech (LEGN) position steady in Q1 2026 at 226,888 shares worth $4.1M. The position accounts for 0.33% of the portfolio, ranked #67.

Ikarian Capital first reported a position in LEGN in Q2 2020 and has held it in 4 quarters since. The position peaked at $4.93M in Q4 2025. 190 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • Ikarian Capital held 226,888 shares of Legend Biotech worth $4.1M as of Q1 2026.
  • Ikarian Capital left its Legend Biotech share count unchanged in Q1 2026.
  • Legend Biotech made up 0.33% of Ikarian Capital's portfolio in Q1 2026, its #67 holding.
  • Ikarian Capital first reported a position in Legend Biotech in Q2 2020 and has held it in 4 quarters since.
  • Ikarian Capital's Legend Biotech position peaked at $4.93M in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.